IP Library Granted Patent US 8,420,827
Granted Patent B2
US 8,420,827 · App. 12/960,937 · Granted Apr 16, 2013

Thiazole derivatives

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,420,827
App. No.
12/960,937
Granted
Apr 16, 2013
Kind
B2
Abstract

Wherein n is an integer of from 0 to 3; R 1A is a 5-membered aromatic heterocyclic group containing at least one oxygen atom; R 2A is —COR 8 (wherein R 8 is aryl); R 3A is hydrogen or lower alkyl; and R 12 represents cycloalkyl, aryl, aralkyl, alicyclic heterocyclic group, aromatic heterocyclic group, alicyclic hetocyclic-alkyl, or aromatic heterocyclic-alkyl, and R 1A , R 2A , R 3A and R 12 are individually optionally substituted.

Claims (19)

1. A thiazole derivative represented by formula (IA):

wherein

R 1A represents a substituted or unsubstituted 5-membered aromatic heterocyclic group containing at least one oxygen atom;

n represents an integer of from 0 to 3;

R 12 represents substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl, a substituted or unsubstituted alicyclic heterocyclic group, a substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted alicyclic heterocyclic-alkyl, or substituted or unsubstituted aromatic heterocyclic-alkyl;

R 3A represents a hydrogen atom, or substituted or unsubstituted lower alkyl; and

R 2A represents —COR 8 (wherein R 8 represents a substituted or unsubstituted aryl);

or a pharmaceutically acceptable salt thereof.

2. The thiazole derivative according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R 1A is substituted or unsubstituted furyl.

3. The thiazole derivative according to claim 1 or a pharmaceutically acceptable salt thereof, wherein n is 0.

4. The thiazole derivative according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R 3A is a hydrogen atom.

5. The thiazole derivative according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R 3A is lower alkyl.

6. The thiazole derivative according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R 1A is furyl.

7. The thiazole derivative according to claim 6 or a pharmaceutically acceptable salt thereof, wherein n is 0.

8. The thiazole derivative according to claim 7 or a pharmaceutically acceptable salt thereof, wherein R 3A is a hydrogen atom.

9. The thiazole derivative according to claim 8 or a pharmaceutically acceptable salt thereof, wherein R 12 is substituted or unsubstituted phenyl.

10. The thiazole derivative according to claim 8 or a pharmaceutically acceptable salt thereof, wherein R 12 is substituted or unsubstituted alicyclic heterocyclic group.

11. The thiazole derivative according to claim 8 or a pharmaceutically acceptable salt thereof, wherein R 12 is substituted or unsubstituted aromatic heterocyclic group.

12. A thiazole derivative represented by any of the following formulae (99), (149) or (170), or a pharmaceutically acceptable salt thereof

Assignments (1)
CHANGE OF NAME AND ADDRESS Recorded Oct 23, 2019
From: KYOWA HAKKO KIRIN CO., LTD.
To: KYOWA KIRIN CO., LTD.
Reel/Frame 050797/0533 →